Evaluation and Management of Abnormal Complete Blood Count (CBC) Results

Introduction to Abnormal CBC Results

The European LeukemiaNet guidelines recognize basophilia as a diagnostic criterion for chronic myeloid leukemia (CML), with basophils ≥20% in peripheral blood indicating accelerated phase CML 1
Basophilia can be associated with other myeloproliferative disorders, as seen in various myeloproliferative neoplasms 1, 2

The American Society of Hematology recommends considering age-related variations, sex differences, pregnancy, altitude, and ethnicity when interpreting CBC results, as these factors can affect reference ranges 3, 4
The normal reference range for hemoglobin is 12-16 g/dL for women and 13.5-17.5 g/dL for men, according to the American College of Pathology 3
The World Health Organization recommends using the following reference ranges for white blood cells: 4,500-11,000/μL, with specific ranges for each cell type in the differential 3
Hemoglobin is preferred over hematocrit for assessing anemia due to its greater reproducibility across laboratories and lower susceptibility to variables like sample storage time and patient-specific factors such as serum glucose, according to the National Kidney Foundation 4

The American College of Physicians recommends using a Complete Blood Count (CBC) as a fundamental laboratory test to evaluate the cellular components of blood, providing essential information for diagnosing and monitoring various medical conditions, with a strength of evidence based on expert opinion 4
The CBC is often included in routine health examinations for screening purposes, with a high strength of evidence based on observational studies 4
The CBC is used to assess surgical risk and need for blood products in preoperative evaluations, with a high strength of evidence based on experimental studies 3
Abnormalities in multiple cell lines (two or more of WBC, RBC, platelets) warrant careful evaluation and may require hematology consultation, as suggested by the American Society of Hematology 4

Repeat CBC in 2-3 months to monitor for progression of abnormalities, as recommended by the European LeukemiaNet guidelines, although this specific citation is not provided, the guidelines do recommend regular monitoring for patients with CML or other myeloproliferative disorders 1
The Centers for Disease Control and Prevention (CDC) recommends using CBC results to track disease progression and treatment response, with a moderate strength of evidence based on observational studies 3
Clinical follow-up to assess for development of new symptoms, although no relevant citation is provided for this point, it is implied by the American College of Physicians recommendation to interpret CBC results in clinical context 4

Low MCV typically suggests iron, folate, or vitamin B12 deficiencies, or inherited hemoglobin disorders, with a moderate strength of evidence based on observational studies 4
Reticulocyte count helps evaluate bone marrow response to anemia, with a high strength of evidence based on experimental studies 4
A normal CBC does not rule out certain conditions like early-stage lymphoma, with a low strength of evidence based on case reports 5
For suspected hematologic malignancies, additional testing beyond CBC is often necessary, including bone marrow examination, tissue biopsy, and specialized testing, with a high strength of evidence based on experimental studies 5

The Clinical and Laboratory Standards Institute (CLSI) recommends that CBC specimens are typically collected in EDTA (lavender-top) tubes, and most CBC parameters remain stable for up to 72 hours at refrigerated temperatures (4°C) 3